The GLP-1 industry is expected to reach $71 billion by 2031, driven by the high rates of overweight and obese Americans. Compounded GLP-1 medications are being offered online at discounted prices compared to branded medications. There is a surge in interest in GLP-1 medications for weight loss, with many companies investing in start-ups and telehealth providers, who are reaching and serving patients online. The rise of GLP-1 medications is impacting bariatric surgery, with fewer people opting for surgery due to the availability of these medications. Bariatric centers are adapting to include GLP-1 medications as a treatment option.
Source link
The Rapid Growth of GLP-1s and Their Impact on Bariatric Surgery
